Replies to post #166653 on Biotech Values

[DewDiligence]

RTRX/TSPT—Last Friday, I tweeted derogatorily about TSPT’s so-called “Tax Benefit Preservation Plan,” which is simply a fancy name for a poison pill:



Now we know why TSPT did it, LOL.

[dav1234]

Transcept rejects Retrophin proposal
Transcept Pharmaceuticals (TSPT) formally rejects Retrophin's (RTRX.PK) $4/share takeout bid.
TSPT says the deal "is not in the best interest of shareholders."
The company previously rejected a lower offer from Retrophin.TSPT +5% AH